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ABSTRACT 
Non-fermentative Gram-negative bacilli (NFGNB) other than Pseudomonas and Acinetobacter species have emerged as 
nosocomial pathogens. No much data is currently available concerning the occurrence of these types of bacteria in Zagazig 
University Hospitals (ZUHs). In this study, the occurrence as well as the antimicrobial susceptibility pattern of unusual NFGNB 
obtained from clinical samples collected from intensive care units (ICUs) of ZUHs was assessed. Additionally, the genetic 
relatedness among the most prevalent unusual NFGNB species was studied. Results: Out of 516 non-repeated clinical sample, 97 
NFGNB (18.7%) were isolated. Among them, 17 unusual NFGNB were identified by API 20NE, accounting for 17.5% of NFGNB 
and 3.3% of all tested samples. Within the unusual NFGNB, Burkholderiacepaciacomplex (Bcc) was the most prevalent species 
accounting for 94.1% of NFGNB and 3.1% of total samples. This was followed by Burkholderia pseudomallei (B. pseudomallei) 
which accounted for 5.9% of NFGNB and 0.2% of all obtained specimens. Tigecycline antibiotic was the most effective 
antibiotic against Bcc isolates (68.8% susceptibility) in disc diffusion method. After random amplified polymorphic DNA 
(RAPD) testing, the obtained Bcc isolates were found to be genetically diverse. This highlights Bcc as an emerging nosocomial 
pathogen in ICUs of ZUHs. Continuous monitoring of the occurrence of Bcc in ICU as well as in other hospital wards is 
warranted. 
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TITRE COURANT : NON – FERMENTAIRE BACILLES GRAM NEGATIF DANS UN HÔPITAL EGYPTIAN 
RESUME 
L’espèce non – fermentaire bacilles Gram négatif (NFGNB) autre que Pseudomonas et Acinetobacteront émergé comme agents 
pathogènes nosocomiaux. Il n’y a pas beaucoup de données actuellement disponibles concernant la présence de ces types de 
bactéries aux hôpitaux universitaire de Zagazig (ZUHs). Dans cette étude, l’occurrence ainsi que le motif de la sensibilité aux 
antimicrobiens des NFGNB inhabituelle obtenue  d’échantillons cliniques prélevésd’unités de soins intensifs de ZHUs ont été 
évalués. Par ailleurs, la parenté génétique entre lesespèces les répandues de NFGNB  inhabituelles a été étudiée. 
Résultats : Sur 516 échantillons cliniques non – répétés, 97 NFGNB (18,7%) étaient isolés. Parmi eux, 17 NFGNB inhabituelle  
ont été identifié par API 20NE, représentant 17,5%  de NFGNB et 3,3% de tous les échantillons testés. Au sein de NFGBN, le 
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complexe Burkholderiacepacia était l’espèce le plus répandureprésentant 94,1% de NFGNB et 3,1%  des échantillonstotal. Ceci a 
été suivi par Burkholderiapseudomallei (B. pseudomallei) lequel représentait 5,9% de NFGNB et 0,2%  de tous spécimens 
obtenus. Tigecycline antibiotique était l’antibiotique le plus efficace contre les isolats Cci (68,8% susceptibilité) dans la méthode 
de diffusion sur disque. Suite a des tests aléatoires d’ADN polymorphique amplifie (RAPD), les isolats Cciobtenus se sont 
trouvés d’êtregénétiquement divers. Ceci souligne Cci comme un pathogènes nosocomiaux émergents en USI de ZUHs. La 
surveillance continue de l’occurrence de Cci en USI, ainsi que dans d’autres services hospitaliers est justifiée. 
 
Mots clés : Inhabituelle, Non fermentaire, bacille gram négative,  unité des soins intensifs. 
Abréviations : Cci :le complexe Burkholderiacepacia ; CF : fibrose kystique ; USI : Unités des soins intensifs ; MIC : 
concentration minimal inhibitrice ; NF : non fermenteurs ; NFGNB : non fermentaire bacilles gram négative ;RAPD ; ZUHs : 
Hôpitaux universitaire de Zagazig. 
 
INTRODUCTION 
Non-fermentative gram-negative bacilli (NFGNB) are 
a diverse group of aerobic non spore-forming bacilli. 
They usually present as saprophytes in the 
environment, particularly, in soil and water. 
Although being saprophytic in nature, NFGNB has 
emerged as important healthcare-associated 
pathogens. Their resistance to disinfectants, in 
addition to their potential to spread from patient to 
patient via fomites, or the hands of medical personnel 
have made them of great concern in hospital settings 
[1] [2]. 
The majority of earlier studies have only focused on 
Pseudomonas spp. and Acinetobacter spp. being the 
most frequently isolated NFGNB, considering the 
unusual group as having a minor clinical significance. 
Nevertheless, serious infections due to NFGNB other 
than Pseudomonas spp. and Acinetobacter spp. are 
currently being reported with increasing frequency 
forming a significant contribution to in-hospital 
mortality, particularly, in immunocompromised 
patients[3] [4]. 
Unfortunately, human infections caused by these 
bacteria are underestimated. This is partly due to 
their complex identification along with their frequent 
misidentification by phenotypic methods commonly 
used in clinical laboratories. Furthermore, the results 
obtained for some of these organisms by disc 
diffusion method do not correlate with successful 
clinical outcome nor with those obtained by the more 
accurate minimal inhibitory concentration (MIC) 
methods [5] [6]. 
As no much data is currently available concerning the 
occurrence of these types of bacteria in Zagazig 
University Hospitals (ZUHs), this study aimed to 
assess the prevalence as well as the antimicrobial 
susceptibility pattern of unusual NFGNB isolated 
from intensive care unit (ICU) patients in ZUHs. A 
further aim was to assess the genetic relatedness 
between the isolates of the most prevalent species 
among this group, considering this a primary step for 
further epidemiologic studies. 
MATERIALS AND METHODS 
Patient selection and collection of samples 
A cross-sectional study was conducted in the Medical 
Microbiology and Immunology Department, Faculty 
of Medicine, Zagazig University, during the period 
from December 2014 to December 2015. One hundred 
and eighty patients (141 male and 39 female), who 
developed different infections at least 48 h after 
admission in either surgical or emergency ICU, were 
enrolled in this study. Their age ranged from one to 
80 years(mean 33.4±15.6). A written informed consent 
was obtained from each patient or from their 
guardians before obtaining the samples. 
Demographic and clinical data of each patient was 
obtained through a worksheet filled for each case. 
Different non-repeated clinical samples (urine, 
endotracheal tube aspirate (ETA), pus and blood) 
were collected from patients according to the site of 
infection, using standard microbiologic methods. This 
study has been approved by the Institutional Review 
Board (IRB) of ZUHs.  
Isolation and Identification  
All samples were cultured on 5% blood agar and 
McConkey agar (Oxoid, England). Culture plates 
were incubated aerobically at 37° C for 48-72 h. 
Identification of non-fermenting colonies (NF) was 
primarily made by their reaction on triple sugar iron 
(TSI) medium (Oxoid, England), gram staining, 
oxidase test and was confirmed by API 20 NE (Bio-
Mérieux, Marcy L´Etoile, France).  
 
Antibiotic Susceptibility Tests 
Isolates that were identified as being NFGNB, with 
the exclusion of Pseudomonas and Acinetobacter spp., 
were tested for their susceptibility to 14 different 
antimicrobials by disc diffusion method. Antibiotic 
discs included cefepime 30 µg, amikacin 30 µg, 
aztreonam  10 µg, tigecycline 15 µg, 
piperacillin/tazobactam (100/10) µg, meropenem 10 
µg, colistin 10 µg, ceftazidime 30 µg, 
trimethoprim/sulphamethoxazole (1.25/23.75) µg, 
piperacillin 100 µg, imipenem 10 µg, 
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cefoperazone/sulbactam (75/30) µg, ciprofloxacin 5 
µg and gentamycin 10 µg. All discs were purchased 
from Bioanalyse (TibbiMalzemelerSanayiveTicaret 
Ltd. Sti., Turkey) except tigecycline was from Oxoid, 
England. In addition, the MICs of ceftazidime, 
meropenem and levofloxacin (Sigma-Aldrich, St. 
Louis, USA) were determined by agar dilution 
method according to EUCAST[7] and CLSI guidelines 
[8]. 
Interpretation of the diameter of inhibition zones for 
meropenem, ceftazidime and TMP-SMX was done 
according to Kirby-Bauer zone diameter 
interpretative standardsas documented in CLSI. 
Those of cefoperazone-sulbactamwere interpreted 
according to the interpretative standards of 
Enterobacteriaceae. The results of other antibiotics were 
interpreted according to that of Pseudomonas 
aeruginosa (P. aeruginosa), as no interpretative 
standards for unusual NFGNB in concern to these 
antibiotics are yet available. Tigecycline inhibition 
zone diameters were interpreted according to FDA 
[9]. Interpretation of agar dilution tests was done 
according to CLSI guidelines. MIC50and MIC90 values 
were calculated according to Schwartz et al. [10]. In 
all antibiotic susceptibility tests, P. aeruginosa ATCC® 
27853 (Global Bioresource, Center of American Type 
Culture Collection KWIK-STIK TM) served as a quality 
control strain. 
Random Amplified Polymorphic DNA (RAPD) 
Genotyping  
The isolates belonging to the most prevalent species 
(Burkholderiacepaciacomplex [Bcc]), were genotyped by 
RAPD technique. Bcc isolates that were identified 
with accuracy of less than 99% by API 20NE were 
subjected to PCR reaction using 16S rDNA primers as 
described previously [11] to ensure their identity. 
RAPD genotyping was achieved by extracting DNA 
from the obtained Bcc isolates using QIAamp DNA 
Mini Kit (QIAGEN GmbH, Germany) according to 
the manufacturer’s instructions, followed by RAPD 
PCR fingerprinting using the primer RAPD-270 (5ʹ-
TGC GCG CGG G-3ʹ) and the cycling conditions 
described previously [12]. Reactions were performed 
in 20 µl reaction mixtures using Maxime PCR PreMix 
Kit (i-Taq) PCR beads (iNtRON Biotechnology, 
Korea). For each reaction, twoµl of extracted DNA 
and 40 µM of the mentioned primer (LGC, Biosearch 
Technologies, USA) were added. Amplification 
reactions were carried out using Veriti 96-well 
thermal cycler (Applied Biosystems, Singapore). PCR 
products were examined after electrophoresis in 1% 
agarose gel and visualized under UV light. Product 
sizes were determined using 50 bp DNA ladder 
(GeneOn, Germany). Interpretation of the fragments 
resulting from RAPD reaction was carried out by 
calculating the similarity index [13]. Then the 
similarity matrix data was subjected to cluster 
analysis with PAST (paleontological statistics) 
software [14] using unweighed pair group method for 
arithmetic average (UPGMA) to generate a 
dendrogram. 
Statistical analysis 
Data was analyzed using Statistical Package for the 
Social Sciences (SPSS version 20.0) software for 
analysis. Chi-square ( )2x  test and Student t-test 
were used to compare two qualitative and 
quantitative groups, respectively. Kruskal-Wallis test, 
a nonparametric test, was used to compare more than 
two groups.Kappa agreement was used to test the 
agreement level between two tests. P value of < 0.05 




Out of 516 cultivated clinical samples, 97 isolates 
(18.7%) were identified as being NFGNB. Among 
them, P. aeruginosa (44/97) had the highest isolation 
frequency (45.4%) followed by Acinetobacterbaumannii 
(36/97, 37.1%) then Bcc (16/97, 16.5%) and finally 
Burkholderia pseudomallei (B. pseudomallei) which had 
the lowest isolation frequency (only one isolate, 
1.03%). After the exclusion of both Pseudomonas spp. 
and Acinetobacter spp., it was shown that unusual 
NFGNB were isolated from 3.3% (17/516) of all tested 
specimens, accounting for 17.5% (17/97) of all 
isolated NFGNB where Bcc isolates were the most 
prevalent (n=16) accounting for 94.1%, followed by B. 
pseudomallei(n=1) accounting for 5.9%. 
 
Out of the 17 unusual NFGNB isolates, 11 isolates 
(64.7%) were obtained from urine specimens taken 
from catheterized patients. The remaining isolates 
(35.3%) were obtained from ETA specimens. No 
isolate was obtained from either blood or pus 
samples. The only isolate of B. pseudomallei was 
obtained from urine sample, while 62.5% of Bcc 
isolates were from urine samples and 37.5% were 
from ETA. 
Nearly half of the patients (9/17 or 52.9%) who 
yielded positive culture for unusual NFGNB were 
below 20 years old (mean 23.4±13.3), while no isolates 
were obtained from patients between 60 and 80 years 
old. Most of unusual NFGNB isolates (15/17 or 
88.2%) were obtained from male patients (88.2%) 
(Table1), though this was insignificant statistically 
when analyzed using Chi-square test (P= 0.29). 
Regarding Bcc isolates, 93.75% were obtained from 
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male patients, the mean duration of ICU stay was 
7.4±3.8 and prior antibiotic administration was 
observed in 62.5% of cases (10/16) (Table 1). 
 
TABLE (1): DEMOGRAPHIC AND CLINICAL DATA OF ICU PATIENTS FROM WHOM UNUSUAL NFGNB ISOLATES WERE OBTAINED 
 
Isolates 1-16 represent Bcc isolates, isolate 17 represents B. pseudomallei
Unfortunately, the only isolate of B. pseudomallei was 
lost during preservation. For this reason, only Bcc 
isolates were subjected to antibiotic susceptibility 
tests. The highest susceptibility ratio in disc diffusion 
method (68.8%) was recorded to tigecycline followed 
by ciprofloxacin (62.5%). On the other hand, no 
isolates were sensitive to ceftazidime, cefepime or 
























Susceptibility ratios of isolated Bcc to 14 antimicrobials in disc diffusion test
 
FIGURE (1): ANTIBIOTIC SUSCEPTIBILITY OF BCC ISOLATES BY DISC DIFFUSION METHOD. ISOLATES THAT HAD INTERMEDIATE 
SUSCEPTIBILITY WERE CONSIDERED RESISTANT IN THIS CHART. THE HIGHEST SUSCEPTIBILITY WAS RECORDED WITH 
TIGECYCLINE. NO ISOLATES WERE SUSCEPTIBLE TO CEFEPIME, CEFTAZIDIME OR PIPERACILLIN. 
The MIC values of ceftazidime, levofloxacin and 
meropenem are presented in Table 2. According to 
CLSI 2015 guidelines, it was found that 62.5% of Bcc 
isolates were susceptible to ceftazidime with 6.25% of 
strains having intermediate susceptibility, 75% were 









Ventilator Antibiotic use 
1 22 Male Urinary  Emergency ICU 5      √       √ √ 
2 15 Male Respiratory  Emergency ICU 4     √     √ - 
3 32 Male  Urinary Emergency ICU 6     √     √ - 
4 
13 Male  
Urinary Emergency ICU 
11     √      √ √ 
5 6 Male  Urinary Emergency ICU 4    √     √ √ 
6 50 Male  Urinary Surgery ICU 3     √     √ √ 
7 17 Male  Respiratory  Surgery ICU 15    √     √ √ 
8 47 Male  Urinary Surgery ICU 5    √     √ √ 
9 16 Male  Urinary Emergency ICU 3    √     √ √ 





Respiratory  Surgery ICU 
7    √     √ - 
12 5 Male  Urinary Emergency ICU 6    √     √ √ 
13 30 Male  Respiratory  Emergency ICU 4    √     √ - 
14 12 Male  Respiratory  Emergency ICU 5    √     √ - 
15 15 Male  Urinary Emergency ICU 10    √     √ √ 
16 18 Male  Respiratory  Surgery ICU 16    √     √ √ 
17  30 Female Urinary Surgery ICU 3    √     √ - 
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to meropenem. When the MIC50 and MIC90 values for 
the three antimicrobials were calculated, those of 
ceftazidime were found to be 8 µg/ml and 512 µg/ml, 
respectively. Regarding levofloxacin, the values were 
1 µg/ml and 32µg/ml, respectively. Finally, the 
values recorded for meropenem were 4 µg/ml and 
128 µg/ml, respectively.  
 
TABLE (2): CEFTAZIDIME, LEVOFLOXACIN AND MEROPENEM MIC VALUES (µg/ml) FOR BCC ISOLATES (N=16) BY 
AGAR DILUTION METHOD 
Antibiotic 




















1  16  2   0.015   
2 0.25   0.03   0.5   
3 8   0.25   0.125   
4 8   0.5     128 
5 
4   1     128 
6   32 2   2   
7   512   32   128 
8   512   8   32 
9 8   1   4   
10 8   0.25   0.125   
11 4   2   2   
12 
4   1     128 
13 
  64   32   32 
14 0.25   0.03   0.5   
15 8   1     128 
16   512   32   128 
P. aeruginosa 









Kruskal Wallis 6.45 
P 0.04* 
S; susceptible, I; intermediate, R; resistant,*significant. 
Considering agar dilution as the reference method, 
good agreement (Kappa 0.5, P 0.001) was found 
between disc diffusion and agar dilution concerning 
the results of meropenem antibiotic. For ceftazidime 
antibiotic, the level of agreement could not be 
analyzed, as all Bcc isolates were resistant to it in the 
disc diffusion method (Table 3). Levofloxacin 
antibiotic was not tested by disc diffusion method. 





TABLE (3): LEVEL OF AGREEMENT BETWEEN DISC DIFFUSION AND MIC RESULTS BY AGAR DILUTION (MIC) OF BCC ISOLATES 
(N=16) FOR CEFTAZIDIME AND MEROPENEM ANTIMICROBIALS 
Meropenem Ceftazidime Antibiotic 
  MIC Disc MIC Disc Isolate 
S R I  R 1 
S S S R 2 
S I S R  3 
R  R S R  4 
R R S R  5 
S I R R  6 
R R R R  7 
R R R R  8 
S S S R  9 
S I S R  10 
S I S R  11 
R R S R  12 
R R R R  13 
S  S S R  14 
R R S R  15 
R R R R  16 
12.44 NA X2 
0.002* ------- P 
0.50 NA* Kappa agreement 
0.001** ------- P 
37.0% 0.0% Disc sensitivity for detection of 
sensitive  
100.0% 100.0% Disc specificity for detection of 
resistant 
R; RESISTANT, S; SUSCEPTIBLE, I; INTERMEDIATE SUSCEPTIBILITY, NA; NOT APPLICABLE, * SIGNIFICANT, **HIGHLY SIGNIFICANT 
Following RAPD analysis of the obtained Bcc isolates 
(Figure 2), the similarity indices ranged from zero to 
0.66 (Table 4). The resulting dendrogram 
demonstrated the presence of two different genetic 
clusters with different subclusters. It also 
demonstrated that the clusters are placed far from 
each other indicating the genetic diversity among the 







L                            1          2           3         4         5         6            7         8          9          10      11        12        13        14        15 
 
FIGURE (2): ELECTROPHORESIS GEL PHOTO DEMONSTRATING RAPD ANALYSIS RESULTS OF 15 BCC ISOLATES. LANE 1 (L) HAS 50-
BP LADDER AND LANES 2-16 DEMONSTRATE RAPD RESULTS OF 15 BCC ISOLATES ARRANGED FROM 1 TO 15, THE SIXTEENTH 
ISOLATE IS NOT INCLUDED IN THIS PHOTO. 
TABLE (4): JACCARD’S SIMILARITY COEFFICIENT (SIMILARITY INDEX) OF THE OBTAINED BCC ISOLATES BY RAPD ANALYSIS 
 Bcc1 Bcc2 Bcc3 Bcc4 Bcc5 Bcc6 Bcc7 
 
Bcc8 Bcc9 Bcc10 Bcc11 Bcc12 Bcc13 Bcc14 Bcc15 Bcc16 
Bcc1 1                
Bcc2 0 1               
Bcc3 0 0 1              
Bcc4 0 0 0 1             
Bcc5 0 0.28 0 0.4 1            
Bcc6 0 0 0.66 0 0 1           
Bcc7 0.18 0.2 0 0.18 0 0.22 1          
Bcc8 0 0.28 0 0 0.25 0.29 0.2 1         
Bcc9 0 0 0 0.2 0 0.29 0.6 0.25 1        
Bcc10 0 0.2 0 0.18 0.2 0 0.33 0 0.2 1       
Bcc11 0 0 0.25 0.6 0.4 0 0 0 0 0.54 1      
Bcc12 0 
 
0 0.25 0 0 0 0 0.2 0 0.36 0.4 1     
263 
 
Bcc13 0 0 0.36 0.15 0 0.18 0.29 0.16 0.5 0.14 0.15 0.31 1    
Bcc14 0.22 0 0 0.25 0.57 0 0 0 0 0 0.25 0 0 1   
Bcc15 0.2 0 0 0.2 0 0 0 0.25 0 0.2 0.2 0.4 0.17 0.29 1  




OF THE OBTAINED BCC 
ISOLATES AFTER 
ANALYSIS USING PAIRED 
GROUP METHOD. NO 
SINGLE ROOT IS 
DETECTED. IT ENDS IN 
TWO MAJOR CLUSTERS 
WITH SUBCLUSTERS 
THAT ARE PLACED FAR 
FROM EACH OTHER. 
 
 
DISCUSSION                                                                  
 The isolation rate of NFGNB (18.7%) recorded in our 
study comes in agreement witha previous Indian 
study carried out in a tertiary care hospital, where it 
was 16.18% [15].Whereas, it comes higher than that 
recorded in another Indian tertiary care hospital 
where it was 9.32% [16]. 
The unusual NFGNB accounted for 3.3% isolation 
frequency among all tested specimens that comes 
much similar to what was reported previously among 
respiratory tract infection in an Indian tertiary care 
hospital (4%) [17]. Bcc was the most prevalent species 
accounting for16.5% of the total NFGNB. This comes 
much higher than what was reported previously 
where Bcc accounted for 4.66% of all isolated non-
fermenters in an Iranian study [18]. Lower ratios were 
also reported in other countries(4.58% and 12.1%) [15] 
[17]. On the other hand, our result is lower than that 
recorded in Latin America, where it accounted for 
47.15% among all NFGNB (83/176) in a surveillance 
study that lasted from 1997 to 2002 [19]. While Bcc 
represented the main unusual NFGNB (16/17, 94.1%) 
in the current study, Stenotrophomonas maltophilia (S. 
maltophilia) was the most frequently isolated species 
among unusual NFGNB in India (45.5%) [17] as well 
as in Saudi Arabia (20.8%) [6]. The different 
identification system used in the previous two studies 
(Vitek 2 system) compared to API 20NE used in the 
current study may have contributed to this difference.   
Only one isolate of B. pseudomalleiwas obtained 
accounting for 5.9% of the unusual NFGNB and 1.03% 
of the total NFGNB. Similar results were reported in a 
previous Indian study where two isolates among 33 
unusual NFGNB were B. pseudomallei accounting for 
6.1% of unusual NFGNB isolated from patients with 
nosocomial pneumonia [17]. 
Urine was the main source of isolation of Bcc (62.5%) 
followed by ETA (37.5%). This comes in contrast to 
the general belief that Bcc is a cause of chronic 
respiratory infection or colonization particularly in 
cystic fibrosis (CF) patients [20]. In a Turkish study, 
ETA was the main source for Bccisolation(58.9%)  [21]. 
However, 62.7% of Bcc were isolated from blood 
specimens in another study [19] and in a previous 
Egyptian study, the highest percent (85.7%) of Bcc 
isolates were from pus specimens [22]. This difference 
could be attributed to the difference in the clinical 
conditions of patients along with different hospital 
wards selected in each study.  
The relatively short ICU stay for patients from whom 
Bcc isolates were isolated (mean 7.4 ± 3.8 days), in our 
study, was an unusual finding. In a previous Turkish 
study, the researchers reported that the mean 
duration of hospitalization for Bcc infected patients 
was 15.2 ± 9.9 days [21]. This may, in some way, point 
to lower compliance to infection control measures 
that may result in a more rapid infection.  
Our study revealed that prior antibiotic use was 
observed in 62.5% of patients positive for Bcc isolates. 
264 
 
Prior antibiotic administration in 38.5% of Bcc infected 
patients was previously reported [21]. This difference 
may be explained by the different treatment policies 
concerning antimicrobials in different hospitals. 
Besides, the researchers of the previous study 
conducted their work in different hospital wards, 
whereas, we focused on ICU patients where excessive 
use of antimicrobials is confronted. 
B. cepaciacomplex bacteria are well known for their 
multidrug resistance. Both intrinsic and acquired 
mechanisms contribute to this phenomenon [23] [24].  
In the current study, the antimicrobial susceptibility 
pattern of the sixteen Bcc isolates was tested by disc 
diffusion and agar dilution methods. In disc 
diffusion, the highest susceptibility rate was observed 
for tigecycline (68.8%) and ciprofloxacin (62.5%). This 
was followed by gentamycin (43.75%), colistin 
(37.5%), amikacin (31.2%), then piperacillin-
tazobactam and imipenem (25% each), co-trimoxazole 
(18.8%), meropenem (18.7%) then both cefoperazone-
sulbactam and aztreonam (12.5% each). On the other 
hand, all isolates were resistant to ceftazidime and 
piperacillin.Different patterns were recorded in 
previous studies [15] [21] [22] [25]but the striking 
point, in our results, is the high level of ceftazidime 
resistance (100%) which was not recorded previously, 
as far as we know. This could be attributed to the 
excess use of 3rd generation cephalosporins in our 
hospital. This clearly highlights the importance of 
local susceptibility tests that should guide treatment 
policies. 
The agar dilution method demonstrated that 62.5%, 
75% and 50% of Bcc isolates were susceptible to 
ceftazidime, levofloxacin and meropenem, 
respectively. Varying results were obtained in 
previous studies [19] [21] [26] [27]. All of them 
recorded Bcc as one of the highly resistant microbes 
encountered. In spite of this, a more recent study 
reported that all Bcc isolated from CF children (B. 
cepacia, B. cenocepacia, and B. multivorans) were 
susceptible to levofloxacin, ceftazidime, and 
meropenem[28]. This indeed confirms the different 
behavior of Bcc isolates in susceptibility tests and 
points to the unpredictable nature of their results. 
Our study recorded higher MIC90 values for the tested 
three antimicrobials, compared to previous works [19] 
[26]. This reflects the higher number of resistant Bcc 
isolates obtained from our hospital compared to the 
other studies. A significant agreement (P 0.001) 
between disc diffusion and agar dilution methods for 
meropenem was found in our study. As all isolates 
were resistant to ceftazidime in disc diffusion, the 
level of agreement with agar dilution could not be 
assessed, but this made the test 100% specific in 
detecting resistant isolates with no false susceptibility 
detected. 
Being the first time to record the isolation of Bcc in 
our hospital,we tried further to assess the genetic 
relatedness of the obtained isolates to be a primary 
step towards more understanding of the spread of 
this organism. Our results demonstrated that Bcc 
isolates obtained from patients in surgery and 
emergency ICUs, belonged to two genetic clusters 
which have further subclusters and which are 
genetically distinct from each other. To date, most of 
the previous studies performed genotyping for Bcc 
obtained from CF patients with their results being 
contradicting [29] [30].  
CONCLUSION 
In conclusion, this study demonstrated that Bcc 
constituted an emerging nosocomial pathogen in 
ICUs of ZUHs with high resistance to different 
antimicrobials. So far, the problem is not great. 
However, this necessitates further studies that 
continuously monitor its occurrence and that assess 
possible sources of infection among ICU patients as 
well as other hospital units.  
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